| CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome A Raghavakaimal, M Cristofanilli, CM Tang, RK Alpaugh, KP Gardner, ... Breast Cancer Research 24 (1), 35, 2022 | 11 | 2022 |
| Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (Leronlimab): A pooled analysis of three clinical trials in patients with mTNBC. DL Adams, A Raghavakaimal, CM Tang, KP Gardner, S Kelly, ... Journal of Clinical Oncology 40 (16_suppl), e13062-e13062, 2022 | 5 | 2022 |
| Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer KP Gardner, M Cristofanilli, S Chumsri, R Lapidus, CM Tang, ... International journal of molecular sciences 23 (13), 7299, 2022 | 1 | 2022 |
| Abstract CT156: Changes in circulating tumor associated cells predicts progression free and overall survival in metastatic TNBC patients after induction of the anti-CCR5 drug … DL Adams, A Raghavakaimal, CM Tang, KP Gardner, NG Ray, ... Cancer Research 82 (12_Supplement), CT156-CT156, 2022 | 1 | 2022 |
| CCR5 upregulation in two subtypes of tumor associated circulating cells predict worse prognosis in metastatic breast cancer A Raghavakaimal, M Cristofanilli, CM Tang, RK Alpaugh, KP Gardener, ... Cancer Res 81 (589), 10.1158, 2021 | 1 | 2021 |
| MA08. 01 Analysis of PD-L1 Expression on Circulating Stromal and Tumor Cells in Lung Cancer Patients Treated with Chemoradiation Therapy and Atezolizumab S Lin, A Augustyn, J He, Y Qiao, Z Liao, A Raghavakaimal, K Gardner, ... Journal of Thoracic Oncology 14 (10), S277, 2019 | 1 | 2019 |
| Combining circulating stromal cells with cell free DNA for increased sensitivity in profiling oncogenic mutations and indicates highly aggressive non small cell lung cancer DL Adams, SH Lin, A Raghavakaimal, G Weiss, A Ford, C Brown, CH Yeh Cancer Res 79, 437, 2019 | 1 | 2019 |
| Transcriptional dysregulation in germline TP53-driven breast cancers N Boruah, R Moses, R Hausler, H Desai, A Le, G Kelly, A Raghavakaimal, ... Cancer Research 84 (6_Supplement), 3018-3018, 2024 | | 2024 |
| Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers N Boruah, D Hoyos, R Moses, R Hausler, H Desai, AN Le, M Good, ... bioRxiv, 2024.04. 03.588009, 2024 | | 2024 |
| Expression of pd-l1 on circulating stromal cells predicts immunotherapy response in unresectable non-small cell lung carcinoma after definitive chemoradiotherapy DL Adams, J He, Y Qiao, KP Gardner, J Haymach, AS Tsao, ... Cancer Research 80 (16), 2020 | | 2020 |
| P2. 01-93 Detection of Giant Cancer-Associated Macrophage-Like Cells After Concurrent Chemoimmunoradiation Is Associated with Poor Survival in NSCLC A Augustyn, D Adams, J He, Y Qiao, T Xu, Z Liao, A Raghavakaimal, ... Journal of Thoracic Oncology 14 (10), S677, 2019 | | 2019 |
| Presence of Giant Circulating Cancer-Associated Macrophage-like Cells after Definitive Chemoradiation Predicts for Progression in Locally Advanced Non-Small Cell Lung Cancer … A Augustyn, DL Adams, J He, Y Qiao, T Xu, A Raghavakaimal, Z Liao, ... International Journal of Radiation Oncology, Biology, Physics 105 (1), S115, 2019 | | 2019 |
| Training and validation study for sequential monitoring of CAMLs in circulation to predict ongoing progression in lung cancer patients undergoing definitive radiotherapy DL Adams, J He, Y Qiao, T Xu, H Gao, J Reuben, R Komaki, Z Liao, ... Journal of Clinical Oncology 37 (15), 2019 | | 2019 |
Daniel L Adamscreatv microtech, Inc.Verified email at creatvmicrotech.com
